Menu
Live
Market Overview
Live indices, gainers & losers
Market Pulse
AI-curated live updates
Market Movers
Top gainers & losers by cap
Market Signals
Value, momentum & analyst signals
Smart Money
Insider & congress trades
Hedge Funds
What 63 elite funds bought & sold
52-Week Highs
Stocks breaking out to new highs
52-Week Lows
Beaten-down stocks near support
High Beta
Stocks that move more than the market
Earnings Calendar
Upcoming earnings dates
Daily
Research
Invest
LIVE
Recursion Pharmaceuticals, Inc.
RXRX
NASDAQ·Healthcare·Biotechnology·Mkt cap $1.6B
$3.80
▲ +3.54%
View full research view
Our plain-language verdict, the thesis, risk factors, and what is changing about the business.
View research view52-Week Range
$2.77 - $7.18
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Down 29.6% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Proprietary AI-powered drug discovery platform
- Advanced computational biology technologies
- Diverse and innovative clinical pipeline
- Strategic pharmaceutical partnerships
Bear Case
1 risk
- Average volatility.
Growth
Mild headwinds expected
Expanding AI capabilities in drug development
Value
Deep value opportunity - significant discount to Biotech & Therapeutics peers
Momentum
Strong
+18.0% over 3m
Quality
Loss-making
Solid business
Dividend
None
No dividend
Smart-money signal
Who's buying RXRX right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: May 4, 2026
MAY 6, 2026
Reported EPS of -$0.22 vs -$0.30 consensus (+26.7% surprise). Revenue of $6.3M vs $15.8M expected (-60.1%).
EPS surprise · last 4Q
1 of 1 beats
Q2 26
+26.7%
Next: May 4, 2026
Revenue trend · last 8Q
—
—
-58%
+9%
+33%
-80%
+688%
-56%
Q2 24
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
$14.4M
$26.1M
$4.5M
$14.7M
$19.1M
$5.2M
$35.5M
$6.5M
Margins · last 8Q
Gross
—
Profit
-1815.6%
Wall Street consensus
4 analysts · 50% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
50%
Hold
50%
Sell
0%
Median Price Target
$5.50
▲ +44.7% vs $3.80
Latest: Morgan Stanley · $5.50 · May 14, 2026
1 analyst covering